Joseph Walter Vazzano Sells 18,666 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) CFO Joseph Walter Vazzano sold 18,666 shares of Abeona Therapeutics stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $5.33, for a total value of $99,489.78. Following the transaction, the chief financial officer owned 568,560 shares in the company, valued at $3,030,424.80. This represents a 3.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Abeona Therapeutics Stock Up 0.9%

Abeona Therapeutics stock traded up $0.05 during mid-day trading on Thursday, hitting $5.36. The company’s stock had a trading volume of 1,363,791 shares, compared to its average volume of 982,818. Abeona Therapeutics Inc. has a 52-week low of $3.93 and a 52-week high of $7.54. The company has a market cap of $290.46 million, a PE ratio of 4.36 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.74 and a quick ratio of 9.53. The firm’s 50 day moving average is $5.07 and its 200 day moving average is $5.64.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. On average, analysts anticipate that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.

Institutional Trading of Abeona Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Boone Capital Management LLC acquired a new position in shares of Abeona Therapeutics during the 2nd quarter worth $7,126,000. Geode Capital Management LLC boosted its holdings in Abeona Therapeutics by 129.1% in the second quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock worth $6,282,000 after purchasing an additional 623,243 shares in the last quarter. Aberdeen Group plc bought a new stake in Abeona Therapeutics in the fourth quarter worth $3,248,000. Cable Car Capital LP acquired a new position in Abeona Therapeutics during the third quarter worth $3,168,000. Finally, JPMorgan Chase & Co. increased its position in Abeona Therapeutics by 255.6% during the second quarter. JPMorgan Chase & Co. now owns 831,132 shares of the biopharmaceutical company’s stock worth $4,721,000 after buying an additional 597,373 shares during the last quarter. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ABEO. Weiss Ratings downgraded shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 24th. Wall Street Zen cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Abeona Therapeutics in a report on Monday, October 13th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.